Waverley Pharma Competitors and Similar CompaniesClear all

Waverley Pharma's competitors and similar companies include Puma Biotechnology, Progenics Pharmaceuticals and RS Research.

	Waverley Pharma Waverley Pharma is a specialty pharma company developing and commercializing therapeutics that aim to cure generic oncology.	Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.	Progenics Pharmaceuticals Progenics Pharmaceuticals is a biopharmaceutical company focused on developing innovative therapeutics for cancer patients.	RS Research RS Research is a pharmaceutical company developing nanomedicines based on innovative drug delivery platforms for targeted cancer therapy.
Founding Date	Founding Date 2014	Founding Date 2010	Founding Date 1986	Founding Date 2015
Type	Type Public	Type Public	Type Subsidiary	Type Private
Tags	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma	Tags Healthcare biotech drug development oncology pharma
Locations	Locations Winnipeg, CA HQ	Locations Los Angeles, US HQ	Locations New York, US HQ Billerica, US	Locations Epalinges, CH HQ
Employees	Employees N/A	Employees 27214% decrease	Employees 49	Employees 254% decrease
Valuation ($)	Valuation ($) 582.4 k	Valuation ($) 136.8 m	Valuation ($) N/A	Valuation ($) N/A
Financial
Revenue (est.)	Revenue (est.) $1.3m (FY, 2025)	Revenue (est.) $228.4m (FY, 2025)	Revenue (est.) $35m (FY, 2019)	Revenue (est.) N/A
Cost of goods	Cost of goods $752k (FY, 2025)	Cost of goods $58.2m (FY, 2025)	Cost of goods $3.2m (FY, 2019)	Cost of goods N/A
Gross profit	Gross profit $597k (FY, 2025)	Gross profit $170.2m (FY, 2025)	Gross profit $31.8m (FY, 2019)	Gross profit N/A
Net income	Net income ($499k) (FY, 2025)	Net income N/A	Net income ($68.6m) (FY, 2019)	Net income N/A